A tumor profiling ovarian cancer therapy has been demonstrated to improve survivorship in women with this type of cancer, Irving-based Caris Life Sciences and Inova Fairfax Hospital announced last weekend, at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
Caris’ ongoing effort to further develop tumor profiling and precision medicine has been reported several times by BioNews Texas.
On the ovarian cancer theraphy, researchers from both the institutions mentioned used Caris Registry, a database of clinicopathologic and outcome variables from consenting patients whose tumors underwent molecular profiling. The Caris Registry included data of a total of 450 patients diagnosed with ovarian, primary peritoneal and fallopian tube carcinomas enrolled between 2010 and 2014, of which 102 were excluded due to non-invasive pathology, non-epithelial histology, and missing or ambiguous treatment information.
Based on chemotherapeutic agents received during their disease course, patients were stratified into “Benefit,” if they received at least one agent designated to be of potential benefit and no agents with potential lack of benefit, and “Lack of Benefit,” when they received at least one agent with potential lack of benefit. Survival was calculated from the date of profiling and from the date of diagnosis to the date of death/censoring using the Kaplan-Meier estimate method.
Of the remaining 348 eligible and evaluable patients, 170 formed the Benefit cohort and the remaining 178 were assigned to the Lack of Benefit cohort. Results showed that patients in the Benefit cohort experienced significantly longer post-profiling survival when compared with patients in the Lack of Benefit cohort. Additionally, there was a trend toward longer overall survival in the Benefit cohort.
This data, fully available in Caris Life Sciences website, led researchers to conclude that tumor molecular profile-directed treatment significantly improves post-profiling survival in patients with ovarian, primary peritoneal and fallopian tube carcinomas. In addition, and despite limited follow-up, trends toward improved overall survival were also demonstrated.
One of the researchers, David Spetzler, who is the vice president of Research & Development at Caris Life Sciences, said in a press release that the team’s findings are “powerful” predictors of therapies that should be avoided for ovarian cancer patients. “A patient’s outcome is strongly influenced by the ability to select appropriate therapies and avoid inappropriate therapies enhanced,” he added.
The entire set of submissions presented at ASCO may be viewed here.